Ki-67 With MRI in Predicting the Complete Pathological Response Post-neoadjuvant Chemotherapy
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Combining MRI and Ki-67 biomarker analysis accurately predicts neoadjuvant chemotherapy (NAC) response in high-risk breast cancer. Integrated models enhance prediction of pathologic complete response (pCR), guiding personalized treatment strategies.
Area Of Science
- Oncology
- Radiology
- Biomarker Analysis
Background
- Neoadjuvant chemotherapy (NAC) is crucial for high-risk breast cancer, with pathologic complete response (pCR) indicating favorable outcomes.
- Accurate prediction of pCR is essential for tailoring NAC and improving patient survival.
- Current assessment methods can be enhanced by integrating imaging and biomarker data.
Purpose Of The Study
- To evaluate the predictive validity of combined MRI and Ki-67 metrics for assessing pCR in breast cancer patients undergoing NAC.
- To compare the performance of integrated MRI-Ki-67 models against single-modality approaches.
Main Methods
- Systematic review and meta-analysis adhering to PRISMA guidelines.
- Inclusion of ten studies assessing NAC-treated breast cancer patients using MRI and Ki-67.
- Evaluation of predictive models using AUC and calibration metrics, focusing on MRI tumor size reduction and Ki-67 levels.
Main Results
- High Ki-67 levels and significant MRI tumor size reduction are consistent predictors of pCR (AUCs near 0.90).
- Integrated MRI-Ki-67 models demonstrated superior predictive accuracy and calibration compared to individual markers.
- Significant heterogeneity (I² = 77%) was observed, indicating variability in assessment protocols.
Conclusions
- Combined MRI and Ki-67 offer robust, non-invasive prediction of pCR, providing structural and biological insights.
- Integrated models represent a significant advancement toward personalized breast cancer treatment.
- Standardization of imaging and biomarker protocols is recommended for improved model reproducibility and clinical integration.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
